FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1/h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 Instruction 1(b). or Section 30(h) of the Investment Company Act of 1940

1. Name ar	<u>V</u>	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]									all application	cable)	g Person(s) to Iss 10% O Other (s		wner				
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST.						3. Date of Earliest Transaction (Month/Day/Year) 07/18/2012									below)			below)	
(Street) CAMBRIDGE MA 02139						f Amer	ndmer	nt, Date	of Origi	nal Fil	ed (Month/D		Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					n	
(City)	(S	tate)	(Zip)																
		Tab	le I - N	lon-Deriv	vative	Sec	uriti	ies Ac	quire	d, D	isposed o	of, or Be	eneficia	lly	Owned	l			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/N						Exec if any	2A. Deemed Execution Date, f any Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			Beneficia Owned F		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			Instr. 4)
Common Stock 07/18/20						12			М		4,000	A	\$15.6	6 630		5,895		D	
Common Stock 07/18/20						12			S ⁽¹⁾		4,000	D	\$53.47	2)(3)	632,895		D		
Common Stock															13,286		I		401(k)
Common Stock														300,000			I	Common Stock neld in rust. ⁽⁴⁾	
		7	able I								posed of converti			y O	wned			·	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	Date, Transa Code (I				6. Date Expirat (Month	tion Da		7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)				9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ow For Dire or I (I) (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares	nber					
Employee Stock Option (right to buy)	\$15.6	07/18/2012			M	4,000		(5))	01/17/2013	Common Stock	4,000	00 \$0.00		94,951		D		

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Boger's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 3. Open market sales reported on this line occurred at a weighted average price of \$53.47 (range \$53.15 to \$53.67).
- $4.\ Common\ stock\ held\ in\ grantor\ retained\ annuity\ trusts.$
- 5. Fully vested.

Remarks:

Valerie L. Andrews, Attorney-

07/19/2012

In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.